Top Companies in Clinical Trial Imaging Market

The global clinical trial imaging market is projected to reach USD 2.07 billion by 2029 from USD 1.42 billion in 2024, at a CAGR of 7.8% during the forecast period. The growth of the pharmaceutical and biotechnology industries, increased investment in research and development, and the rise in Contract Research Organizations (CROs) are the main drivers of the clinical trial imaging market's expansion. But the biggest barriers preventing the market from developing are the high costs of clinical trial execution and imaging system implementation.

The major players in this market are ICON Plc (Ireland), Clario (US), Medpace (US), IXICO Plc (UK), and Resonance Health Ltd. (Australia). Other players such as Radiant Sage (US), WCG Clinical (US), Voiant (US), Cardiovascular Imaging Technologies (US), Medical Metrics Inc. (US), Prism Clinical Imaging (US), Boston Imaging Core Lab (US), Anagram 4 Clinical Trials (Spain), Calyx (UK), Biospective Inc. (Canada), Proscan Imaging (US), Micron Inc. (Japan), Imaging Endpoints (US), Perspectum (UK), Pharmtrace (Germany), Navitas Life Sciences (US), Median Technologies (France) and Invicro, LLC. (US), Image Core Lab (India), Image Analysis Group (UK).

To know about the assumptions considered for the study download the pdf brochure

ICON held a strong position at the forefront of the clinical trial imaging market as of 2023. The company's extensive distribution networks in North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa have maintained its dominance. To further solidify its dominance in this industry, ICON uses non-organic expansion techniques, with a focus on acquisitions that bolster its current business divisions. For example, in October 2023, ICON acquired 100% of the equity of BioTel Research, LLC, a leading medical imaging and cardiac safety monitoring service provider. This part of the business was formerly known as Philips Pharma Solutions.  The company’s foothold in the market is primarily attributed to several factors, such as its strong technical and service capabilities, good client relationships, and diversified service offerings.

In the clinical trial imaging market, Medpace Holdings, Inc. held the second-best position in 2023. The company's strong sales and distribution network is responsible for its dominant position. The company’s leading position in this market can be attributed to its strong global sales and distribution network, enabling it to market its services and solutions in various countries. Its increasing focus on emerging markets has also supported revenue growth and has increased its overall revenue—the company’s overall revenue increased from USD 0.93 billion in 2020 to USD 1.89 billion in 2023. The organization pursues non-organic tactics like acquisitions and devotes a significant amount of its revenue to research and development (R&D). Through completely owned subsidiaries and representative sales offices, the company operates in North America, Europe, Asia, South America, Africa, and Australia.

Related Reports:

Clinical Trial Imaging Market by Software & Service (Operational Imaging, Trial Design), Modality (CT, MRI, X-Ray, PET, Ultrasound), Therapeutic Area (Infectious, Oncology, CNS, CVD), End User (Pharma, Biotech, CROs) - Global Forecast to 2029

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]